Benefits of telaprevir triple therapy appear to balance risks

10/1/2013 | Healio (free registration)

Treatment-naive hepatitis C patients with advanced fibrosis and patients who had relapsed responded well to a 12-week course of telaprevir combined with 24 weeks of pegylated interferon alfa-2b and ribavirin in a prospective, multicenter study. Sustained virological response rate in these patients was more than 80%. Prior partial-response patients had a 50% SVR and null-response patients had a 16.7% SVR.

View Full Article in:

Healio (free registration)

Published in Brief: